Compounds and methods for modulating OB-cadherin mediated cell adhesion
AssigneeAdherex Technologies, Inc.
InventorsOrest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
Life of this patent
Estimating the term…
Abstract
Modulating agents for inhibiting or enhancing OB-cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) an OB-cadherin CAR sequence; (b) a peptide analogue or peptidomimetic thereof; (c) an antibody or antigen-binding fragment thereof that specifically binds an OB-cadherin CAR sequence; and/or (d) a polynucleotide encoding any of the foregoing peptide sequences. Methods for using such modulating agents for modulating OB-cadherin-mediated cell adhesion in a variety of contexts are also provided.
Claims14
A cell adhesion modulating agent, wherein the agent is a peptide four to nine amino acids in length that, at a concentration of 1 mg/mL, detectably inhibits OB-cadherin mediated cell adhesion, and wherein the peptide consists of (a) a native OB-cadherin CAR that comprises the sequence DDK and (b) optionally, a residue on one or both sides of the CAR sequence to facilitate cyclization.
A cell adhesion modulating agent linked to a drug, wherein the agent is a 3-50 amino acid peptide that, at a concentration of 1 mg/mL, detectably inhibits OB-cadherin mediated cell adhesion, and wherein the peptide consists of (a) a native OB-cadherin CAR sequence that comprises the sequence DDK and (b) optionally, a residue on one or both sides of the CAR sequence to facilitate cyclization.
A cell adhesion modulating agent linked to a detectable marker, wherein the agent is a 3-50 amino acid peptide that, at a concentration of 1 mg/mL, detectably inhibits OB-cadherin mediated cell adhesion, and wherein the peptide consists of (a) a native OB-cadherin CAR sequence that comprises the sequence DDK and (b) optionally a residue on one or both sides of the CAR sequence to facilitate cyclization.
A cell adhesion modulating agent linked to a targeting agent, wherein the modulating agent is a 3-50 amino acid peptide that, at a concentration of 1 mg/mL, detectably inhibits OB-cadherin mediated dell adhesion, and wherein the peptide consists of (a) a native OB-cadherin CAR sequence that comprises the sequence DDK and (b) optionally, a residue on one or both sides of the CAR sequence to facilitate cyclization.
A cell adhesion modulating agent that is a 3-50 amino acid peptide that, at a concentration of 1 mg/mL, detectably inhibits OB-cadherin mediated cell adhesion, wherein the peptide consists of (i) a native OB-cadherin CAR sequence that comprises the sequence DDK and (ii) optionally, a residue on one or both sides of the CAR sequence to facilitate cyclization, wherein the agent further comprises one or more of:
- (a) a cell adhesion recognition sequence selected from the group consisting of HAV, RGD, YIGSR (SEQ ID NO:15), YAT, FAT, YAS, RAL, LYHY, SHAVSS (SEQ ID NO:29) and AHAVDI (SEQ ID NO:30);
- and/or
- (b) an antibody or antigen-binding fragment thereof that specifically binds to a CAR sequence selected from the group consisting of HAV, RGD, YIGSR (SEQ ID NO:15), YAT, FAT, YAS, RAL, LYHY, SHAVSS (SEQ ID NO:29) and AHAVDI (SEQ ID NO:30).
A composition comprising:
- (a) a cell adhesion modulating agent that is a 3-50 amino acid peptide that, at a concentration of 1 mg/mL, detectably inhibits OB-cadherin mediated cell adhesion, wherein the peptide consists of (i) a native OB-cadherin CAR sequence that comprises the sequence DDK and (ii) optionally, a residue on one or both sides of the CAR sequence to facilitate cyclization, in combination with
- (b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.